Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada

[1]  J. Wish.  Perspective: Will We Ever Know the Optimal Hgb Level in ESRD? , 2018, Journal of the American Society of Nephrology : JASN.

[2]  Björn Eliasson,et al.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[3]  J. Sterne,et al.  Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13 , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Mark S Levenson,et al.  Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. , 2016, JAMA internal medicine.

[5]  Validity of Canadian discharge abstract data for hypertension and diabetes from 2002 to 2013. , 2016, CMAJ open.

[6]  Chuan-Fen Liu,et al.  Decisions about Renal Replacement Therapy in Patients with Advanced Kidney Disease in the US Department of Veterans Affairs, 2000-2011. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[7]  A. Collins,et al.  Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  J. Carrero,et al.  Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  K. Rothman,et al.  Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. , 2016, Journal of the American Society of Nephrology : JASN.

[10]  Vincent Mor,et al.  Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. , 2015, Health services research.

[11]  A. Collins,et al.  Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  Ahmed A. Al-Jaishi,et al.  Canadian Organ Replacement Register (CORR): reflecting the past and embracing the future , 2014, Canadian journal of kidney health and disease.

[13]  J. Adamson,et al.  Notice , 2012, Kidney International Supplements.

[14]  M. Tonelli,et al.  Rates of treated and untreated kidney failure in older vs younger adults. , 2012, JAMA.

[15]  Marcello Tonelli,et al.  The new FDA labeling for ESA--implications for patients and providers. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[16]  J. Adamson,et al.  KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .

[17]  A. Garg,et al.  A validation study of the Canadian Organ Replacement Register. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[18]  C. Charytan.  Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[19]  D. Revicki,et al.  Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  R. Garrick.  A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[21]  S. Solomon,et al.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.

[22]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[23]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[24]  R. Foley,et al.  Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.